Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma

Background EXCELS, a postmarketing observational cohort study, was a commitment to the US Food and Drug Administration to assess the long-term safety of omalizumab in an observational setting, focusing predominantly on malignancies. Objective The aim of this study was to examine a potential associat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2017-05, Vol.139 (5), p.1489-1495.e5
Hauptverfasser:	Iribarren, Carlos, MD, MPH, PhD, Rahmaoui, Abdelkader, MD, Long, Aidan A., MD, Szefler, Stanley J., MD, Bradley, Mary S., MS, Carrigan, Gillis, PhD, MSc, Eisner, Mark D., MD, MPH, Chen, Hubert, MD, MPH, Omachi, Theodore A., MD, MBA, Farkouh, Michael E., MD, MSc, Rothman, Kenneth J., DrPH
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse event Age Allergy and Immunology Angina Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use arterial thromboembolic event Arteriosclerosis Asthma Asthma - drug therapy Asthma - epidemiology C-reactive protein Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular system Cerebral infarction Cerebrovascular Disorders - epidemiology Cerebrovascular system Chronic obstructive pulmonary disease Circulation Clinical trials Cohort analysis Complications Condensates Congenital defects Congestive heart failure Coronary artery disease Corticoids Drug therapy Emergency medical services Female Glucocorticoids Hemorrhage Humans Hypersensitivity Immunoglobulin E Immunotherapy Incidence Male Malignancy Middle Aged moderate to severe asthma Monoclonal antibodies Motivation Myocardial infarction omalizumab Omalizumab - adverse effects Omalizumab - therapeutic use Patient safety Patients Pharmaceuticals Population studies Product Surveillance, Postmarketing Prospective Studies Quality of life Respiration Rheumatoid arthritis Risk assessment Risk factors Safety serious adverse event Side effects Skin Stroke Thrombosis Transient ischemic attack Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!